Baxter pumps new life into haemodialysis offering with $4bn Gambro buy
This article was originally published in Clinica
Executive Summary
Baxter International has agreed to acquire haemodialysis specialist Gambro for SEK26.5 billion ($4.0 billion) in cash and debt, confirming recent media speculation. The deal gives Baxter a “comprehensive dialysis product portfolio, complements [its] global home dialysis offerings, and positions the company to better meet the evolving needs of the large and growing dialysis market”, the company stated.